Date: 2015-02-27
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 13th International congress on Targeted Anticancer Therapies (TAT 2015) held in Paris from March 2 to 4, 2015
Company: GamaMabs Pharma (France)
Product: 3C23K monoclonal antibody (GM102)
Action
mechanism: monoclonal antibody. 3C23K is a monoclonal antibody which targets Anti-Mullerian Human Receptor 2 (AMHR2 / MISR2) in ovarian cancer. 3C32K is a ‘low-fucose’ antibody that mobilizes tumor immune cells and targets the anti-Müllerian hormone receptor (AMHR2). The expression of this hormone is limited to adult ovaries (where it is expressed by the granulosa cells) and testicles (by the Leydig cells). AMHR2 is also expressed in the majority of gynecological cancers, such as ovarian and endometrial cancers, being detected in around 65% of cases.
Disease: ovarian cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On February 27, 2015, GamaMabs Pharma announced the presentation of a poster at the 13th International congress on Targeted Anticancer Therapies (TAT 2015) held in Paris from March 2 to 4, 2015. The poster « In vivo synergism between chemotherapy and the 3C23K monoclonal antibody targeting the AMH-type II receptor in ovarian cancer PDX models» with F. Nemati and D. Decaudin from Curie Institute as principal authors, and in collaboration with GamaMabs Pharma scientists, is presented during the TAT congress in Paris on the 2nd of March 2015. It summarizes, in a study performed on 14 ovarian cancer Patient Derived Xenografts (PDX) models, out of which 43% (6 PDX) express AMHR2 detected with three different techniques, that 3C23K increases the anti-tumoral efficacy of conventional first line chemotherapy (carboplatin/paclitaxel) in ovarian cancers. In AMHR2 expressing models, this efficacy translates in an increase of complete response in all arms where the antibody is associated with chemotherapy. Those results confirm the interest in developing this combination in patients with ovarian cancer expressing AMHR2, cancer which prognostic remains dismal. GamaMabs Pharma plans the beginning of clinical trials with 3C23K in the second half of 2015. * On September 4, 2014, GamaMabs Pharma, which holds exclusive rights on 3C23K monoclonal antibody targeting AMHR2 / MISR2, announced the presentation of results at the 10th Biennial Ovarian Cancer Research Symposium of Seattle on 8-9 of September 2014. The poster “In vivo synergism between chemotherapy and the 3C23K monoclonal antibody directed against the anti-Müllerian hormone type 2 receptor in ovarian cancer patient derived xenografts” by F Nemati, Dr Didier Decaudin et al., from Institut Curie in collaboration with GamaMabs Pharma, summarizes the study based on 14 Patient Derived Xenografts confirming AMHR2 expression in ovarian cancer, and describes 3C23K synergistic therapeutic effect in combination with standard chemotherapy.
